Amgen (AMGN) Q3 2025: Volume Growth Hits 14% as 16 Drugs Post Double-Digit Gains
Amgen’s Q3 saw broad-based volume gains and 16 products with double-digit growth, reinforcing the company’s diversified innovation engine amid ongoing price pressures. Management raised guidance as pipeline execution and commercial expansion underpin confidence for 2026. Investors should watch for pivotal data readouts, particularly in obesity, cardiovascular, and oncology, that could reshape Amgen’s growth profile.
Summary
- Pipeline Breadth Delivers: Sixteen products posted double-digit growth, with biosimilars and rare disease portfolios accelerating.
- Innovation and Access Moves: Amgen Now platform and new clinical data aim to expand patient reach and drive future share gains.
- 2026 Setup Strengthens: Raised guidance and upcoming late-stage data readouts position Amgen for multi-year growth inflection.
Performance Analysis
Amgen’s Q3 results were defined by broad-based volume expansion and commercial execution across its portfolio, with revenues up 12% and volume up 14% year-over-year. The company highlighted that 16 products achieved double-digit growth, and 14 now annualize above $1 billion in sales, signaling a healthy diversification beyond legacy blockbusters. Key growth drivers include Repatha, PCSK9 inhibitor for cholesterol, which grew 40% and is now annualizing at $3 billion, and Avenity, a bone-building therapy, up 36% with strong U.S. and Japan performance. The rare disease portfolio, now annualizing at over $5 billion, posted 13% growth, while biosimilars, copycat biologic drugs, surged 52% and are annualizing near $3 billion.
Operating margin landed at 47%, reflecting increased R&D investment, particularly in late-stage programs like Meritide (obesity) and Opasoran (cardiovascular). Free cash flow reached $4.2 billion for the quarter, supporting both capital returns and pipeline reinvestment. Amgen’s U.S.-centric manufacturing base and $3 billion in planned 2025 capex reinforce supply chain resilience and capacity for future launches.
- Volume-Driven Outperformance: 14% volume growth offset industry-wide pricing headwinds, demonstrating strong demand elasticity and portfolio relevance.
- R&D Step-Up: Non-GAAP R&D spend rose 31%, reflecting pipeline acceleration and business development transactions.
- Biosimilar Momentum: 52% sales growth in biosimilars, with PavBlue (ILEA biosimilar) gaining rapid traction among retina specialists.
Management’s guidance raise for both revenue and EPS reflects confidence in continued portfolio momentum, pipeline execution, and the durability of recent volume gains, even as pricing and competitive pressures persist in legacy categories.
Executive Commentary
"Sixteen of our products grew at double-digit rates. And 14 are now annualizing at over a billion dollars in sales. Our broad base of innovative medicines is generating powerful momentum and gives us confidence in our ability to sustain long-term growth."
Bob Bradway, Chairman and Chief Executive Officer
"We are pleased with our strong third quarter performance and remain on track with our 2025 full-year goals and long-term objectives. The benefit of our portfolio was clearly seen this quarter, and coupled with momentum across the business, we are raising our 2025 guidance ranges for both revenue and non-GAAP earnings per share."
Peter Griffith, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Portfolio Diversification and New Launches
Amgen’s growth is increasingly driven by a diversified set of assets spanning general medicine, rare disease, oncology, inflammation, and biosimilars. Repatha and Avenity are expanding addressable populations through new indications and direct-to-patient platforms, while rare disease launches (e.g., Uplizna in IgG4-related disease) are building early momentum. Biosimilars are now a meaningful profit engine, with new launches like PavBlue accelerating market penetration and cash flow.
2. Pipeline Execution and R&D Discipline
The company is executing on a robust late-stage pipeline, notably in obesity (Meritide, with six Phase III studies underway), cardiovascular (Opasoran, OceanA outcomes study), and oncology (Imdeltra, Blinzaito, Zaluridamig). R&D investment is up sharply, but management emphasized a “step change” rather than a new baseline, pointing to a normalization of spend as major studies complete. AI and digital platforms are being leveraged across discovery, development, and manufacturing to accelerate productivity and trial enrollment.
3. Access and Affordability Initiatives
Amgen Now, the company’s direct-to-patient platform, launched with Repatha at a price nearly 60% below the U.S. list price, signaling a proactive approach to affordability and payer access. This move aims to expand market reach, particularly in underpenetrated segments like primary prevention in cardiovascular disease.
4. Manufacturing Scale and U.S. Base
With $3 billion in 2025 capex and a U.S.-anchored manufacturing network, Amgen is investing to support global demand and mitigate supply chain risk. This operational backbone enables rapid scale-up for new launches and underpins confidence in long-term volume growth.
5. Capital Allocation and Balance Sheet Reset
Amgen retired $10.5 billion in debt over two years, returning to pre-Horizon acquisition leverage ahead of plan. With a competitive dividend and a focus on early-stage business development, the company is positioned for both organic and external growth without overextending its balance sheet.
Key Considerations
Amgen’s Q3 demonstrated that its multi-asset, multi-therapy strategy is delivering both top-line and bottom-line leverage, but the next leg of growth depends on pivotal pipeline readouts and commercial execution in new indications.
Key Considerations:
- Obesity Market Entry: Meritide’s clinical profile and dosing flexibility could differentiate Amgen in a massive but underpenetrated obesity market, with Phase II data to inform maintenance and long-term strategy.
- Cardiovascular Expansion: Repatha’s Vesalius CV outcomes data (to be presented at AHA) could unlock primary prevention and drive a step-change in addressable market.
- Biosimilar Policy Environment: Regulatory shifts (e.g., FDA guidance on comparative efficacy studies) may lower barriers to entry but Amgen’s manufacturing and process expertise remain a competitive moat.
- Rare Disease Uptake: Early momentum in Uplizna’s new indications (e.g., IgG4-related disease, GMG) is promising, but market education and diagnosis rates will be key to sustained growth.
Risks
Amgen faces persistent pricing pressure across legacy categories, rising R&D costs as the pipeline matures, and evolving biosimilar competition that could erode share in established franchises. Key pipeline readouts (e.g., Opasoran, Meritide) carry execution and clinical risk, and regulatory or reimbursement policy changes could alter the trajectory for both branded and biosimilar assets. Management’s increased investment in innovation must translate into commercial wins to justify elevated spend and maintain industry-leading margins.
Forward Outlook
For Q4 2025, Amgen guided to:
- Revenue of $35.8 to $36.6 billion for full-year 2025
- Non-GAAP EPS of $20.60 to $21.40
For full-year 2025, management raised guidance for both revenue and EPS, reflecting:
- Continued volume-driven growth across key therapeutic areas
- Ongoing R&D investment, especially in late-stage pipeline assets
Management highlighted the impact of implemented tariffs, normalization of R&D spend post-step change, and the potential for further upside from upcoming clinical data and new launches.
Takeaways
Amgen’s Q3 performance validates its diversified, innovation-led model, but future upside hinges on late-stage pipeline execution and the ability to scale new launches across a complex global market.
- Portfolio Breadth Drives Resilience: Double-digit growth across 16 products and strong biosimilar momentum provide a buffer against pricing headwinds and legacy erosion.
- Pipeline Readouts Are Critical: Upcoming data in obesity, cardiovascular, and oncology will determine whether Amgen can sustain and accelerate its volume-driven growth.
- Execution on Access and Affordability: Programs like Amgen Now and payer engagement are crucial to unlocking underpenetrated patient segments and defending share in competitive markets.
Conclusion
Amgen exits Q3 with commercial momentum, a reloaded balance sheet, and a late-stage pipeline poised for pivotal readouts. While the company’s multi-pronged approach is delivering today, sustained outperformance will require flawless execution on both clinical and commercial fronts as market dynamics evolve.
Industry Read-Through
Amgen’s results reinforce the power of diversified pipelines and biosimilar scale in navigating industry-wide price deflation and payer scrutiny. The direct-to-patient Amgen Now launch sets a precedent for large biopharma to proactively address affordability and access, a theme likely to accelerate across the sector. Investors should monitor how regulatory changes in biosimilars and payer dynamics in obesity and cardiovascular care shape both competitive intensity and the size of addressable markets for incumbents and new entrants alike.